Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
NSPR

NSPR - InspireMD Inc Stock Price, Fair Value and News

2.60USD-0.02 (-0.76%)Market Closed

Market Summary

NSPR
USD2.60-0.02
Market Closed
-0.76%

NSPR Stock Price

View Fullscreen

NSPR RSI Chart

NSPR Valuation

Market Cap

64.8M

Price/Earnings (Trailing)

-2.86

Price/Sales (Trailing)

10.01

EV/EBITDA

-2.83

Price/Free Cashflow

-3.78

NSPR Price/Sales (Trailing)

NSPR Profitability

Operating Margin

62.48%

EBT Margin

-306.48%

Return on Equity

-64.67%

Return on Assets

-53.99%

Free Cashflow Yield

-26.47%

NSPR Fundamentals

NSPR Revenue

Revenue (TTM)

6.5M

Rev. Growth (Yr)

21.95%

Rev. Growth (Qtr)

-14.2%

NSPR Earnings

Earnings (TTM)

-22.7M

Earnings Growth (Yr)

-65.23%

Earnings Growth (Qtr)

-30.1%

Breaking Down NSPR Revenue

Last 7 days

-3.3%

Last 30 days

9.2%

Last 90 days

13.5%

Trailing 12 Months

30.7%

How does NSPR drawdown profile look like?

NSPR Financial Health

Current Ratio

7.9

Debt/Equity

0.03

Debt/Cashflow

-15.11

NSPR Investor Care

Shares Dilution (1Y)

198.33%

Diluted EPS (TTM)

-0.62

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20246.5M000
20235.2M5.3M5.5M6.2M
20224.7M5.2M5.5M5.2M
20212.5M3.2M3.3M4.5M
20204.3M3.3M3.3M2.5M
20193.0M3.4M3.5M3.7M
20183.2M3.6M3.6M3.6M
20171.9M2.0M2.2M2.8M
20162.4M2.3M2.1M1.9M
20151.8M2.3M2.7M2.3M
20146.1M4.8M3.5M2.8M
20134.3M4.9M5.9M6.1M
20125.5M5.3M3.9M3.9M
20114.5M4.7M5.4M6.0M
201003.9M4.4M4.9M
20090003.4M

Tracking the Latest Insider Buys and Sells of InspireMD Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 05, 2024
stuka paul
acquired
120,986
1.3827
87,500
-
May 28, 2024
roubin gary s
acquired
42,345
1.3827
30,625
-
Jan 23, 2024
shore craig
acquired
-
-
238,625
cfo and cao
Jan 23, 2024
roubin gary s
acquired
-
-
29,032
-
Jan 23, 2024
berman michael
acquired
-
-
29,032
-
Jan 23, 2024
kester thomas j
acquired
-
-
29,032
-
Jan 23, 2024
stuka paul
acquired
-
-
43,548
-
Jan 23, 2024
verta patrick
acquired
-
-
85,720
evp clinical/medical affairs
Jan 23, 2024
slosman marvin
acquired
-
-
563,499
ceo and president
Jan 23, 2024
arnold kathryn
acquired
-
-
29,032
-

1–10 of 50

Which funds bought or sold NSPR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 15, 2024
MILLENNIUM MANAGEMENT LLC
added
21.06
-8,903
969,747
-%
May 15, 2024
PURA VIDA INVESTMENTS, LLC
unchanged
-
-198,183
1,067,770
0.18%
May 15, 2024
Nantahala Capital Management, LLC
reduced
-50.00
-6,715,780
4,897,710
0.28%
May 15, 2024
Soleus Capital Management, L.P.
unchanged
-
-606,239
3,266,300
0.24%
May 15, 2024
Jetstream Capital LLC
new
-
82,954
82,954
3.60%
May 15, 2024
MARSHALL WACE, LLP
unchanged
-
-948,806
4,278,930
0.01%
May 15, 2024
MORGAN STANLEY
unchanged
-
-27,947
150,572
-%
May 15, 2024
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
unchanged
-
-1.00
2.00
-%
May 15, 2024
NOTTINGHAM ADVISORS, INC.
added
20.00
853
71,103
0.01%
May 15, 2024
ORBIMED ADVISORS LLC
unchanged
-
-938,485
5,056,380
0.09%

1–10 of 33

Are Funds Buying or Selling NSPR?

Are funds buying NSPR calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own NSPR
No. of Funds

Unveiling InspireMD Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 17, 2024
rosalind advisors, inc.
9.9%
2,492,765
SC 13G/A
Apr 25, 2024
rosalind advisors, inc.
9.9%
686,062
SC 13G/A
Feb 14, 2024
nantahala capital management, llc
9.9%
2,162,392
SC 13G
Feb 14, 2024
rosalind advisors, inc.
9.9%
989,940
SC 13G/A
Feb 14, 2024
orbimed advisors llc
9.9%
2,133,405
SC 13G
Jun 16, 2023
shore craig
8.01%
1,700,159
SC 13D
Jun 08, 2023
rosalind advisors, inc.
9.9%
1,860,405
SC 13G
May 24, 2023
soleus private equity fund iii, l.p.
9.9%
2,199,118
SC 13G
May 22, 2023
marshall wace north america l.p.
9.9%
1,860,405
SC 13G
Feb 11, 2022
lind global macro fund lp
2.1%
177,333
SC 13G/A

Recent SEC filings of InspireMD Inc

View All Filings
Date Filed Form Type Document
Jun 13, 2024
8-K
Current Report
Jun 12, 2024
8-K
Current Report
Jun 07, 2024
4
Insider Trading
May 31, 2024
424B5
Prospectus Filed
May 31, 2024
8-K
Current Report
May 30, 2024
4
Insider Trading
May 28, 2024
8-K
Current Report
May 17, 2024
SC 13G/A
Major Ownership Report
May 14, 2024
8-K
Current Report
May 13, 2024
10-Q
Quarterly Report

Peers (Alternatives to InspireMD Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
180.0B
40.3B
-0.56% 0.17%
31.97
4.46
-2.84% -3.00%
67.0B
19.7B
-1.30% -8.44%
50.29
3.4
4.82% -17.56%
20.4B
3.9B
-2.39% -15.83%
44.2
5.22
5.72% 46.72%
17.2B
14.9B
-4.28% -22.37%
6.49
1.15
2.98% 207.68%
MID-CAP
9.7B
3.5B
-1.42% 26.61%
30.88
2.73
6.16% 35.06%
8.5B
12.4B
-8.96% -11.44%
21.86
0.68
-0.93% -18.83%
8.0B
2.6B
-4.13% -24.00%
-24.93
3.09
-6.25% -68.58%
5.5B
3.9B
-5.09% -29.87%
-58.03
1.41
0.23% 90.80%
3.4B
387.1M
-0.21% 32.29%
-215.53
8.87
30.82% 65.57%
2.0B
6.6B
-10.10% -15.73%
10.59
0.31
2.78% -0.87%
SMALL-CAP
1.5B
3.2B
18.01% 16.23%
-2.22
0.48
7.94% -1695.32%
385.1M
169.3M
1.48% -3.53%
-5.01
2.28
7.49% -244.90%
248.7M
324.0M
0.65% -42.87%
-1.29
0.77
-3.19% -337.41%
50.6M
50.5M
3.55% -78.84%
-2.22
1
14.25% -10.06%
1.8M
3.7M
-17.65% -79.41%
-0.15
0.49
5.77% 8.23%

InspireMD Inc News

Latest updates
MarketBeat11 Jun 202409:45 am
Defense World03 Jun 202409:00 am
MarketBeat26 May 202406:56 am

InspireMD Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-14.2%1,511,0001,761,0001,556,0001,649,0001,239,0001,026,0001,431,0001,531,0001,183,0001,380,0001,071,0001,038,0001,006,000158,000980,000313,0001,034,0001,013,000939,0001,354,000415,000
Gross Profit-42.2%292,000505,000438,000491,000373,000198,000366,000431,000122,000294,00092,000262,000106,000-390,000298,000-120,000295,000259,000128,000442,000-73,000
Operating Expenses22.1%7,706,0006,313,0006,077,0005,806,0004,754,0005,134,0004,976,0005,112,0004,608,0004,225,0004,123,0003,702,0003,420,0003,328,0002,493,0002,326,0002,316,0002,765,0002,125,0002,625,0003,057,000
  S&GA Expenses-5.5%1,237,0001,309,000876,000892,000788,0001,087,000845,000986,000746,000761,000802,000636,000708,000617,000485,000377,000624,000605,000537,000620,000634,000
  R&D Expenses29.0%2,625,0002,035,0002,110,0001,993,0001,843,0002,013,0002,061,0002,056,0001,680,0001,534,0001,495,0001,290,000839,000720,000546,000444,000523,000522,000442,000865,0001,125,000
EBITDA Margin4.3%-3.03-3.16-3.23-3.30-3.38-3.42-3.07-3.19-3.29-3.14-3.00-3.08---------
Earnings Before Taxes-------4,817,000-4,529,000-4,636,000-4,481,000-4,052,000-4,071,000-3,507,000-3,243,000---2,480,000--2,533,000-2,070,000-2,206,000-3,207,000
EBT Margin4.2%-3.06-3.20-3.38-3.45-3.53-3.57-3.20-3.34-3.45-3.31-3.22-3.31---------
Net Income-30.1%-7,032,000-5,405,000-5,178,000-5,077,000-4,256,000-4,845,000-4,529,000-4,636,000-4,481,000-4,097,000-4,071,000-3,507,000-3,243,000-3,853,000-2,233,000-2,480,000-1,978,000-2,557,000-2,070,000-2,206,000-3,207,000
Net Income Margin-9.2%-3.50-3.21-3.54-3.50-3.49-3.58-3.21-3.35-3.46-3.32-4.48-4.03---------
Free Cashflow-19.7%-5,259,000-4,392,000-4,139,000-3,370,000-4,856,000-3,290,000-5,330,000-3,224,000-4,171,000-3,008,000-4,297,000-2,582,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-11.8%42.0048.0050.0054.0020.0025.0028.0033.0035.0040.0043.0046.0049.0018.0016.0018.007.0010.0012.009.0010.00
  Current Assets-12.8%39.0044.0047.0051.0017.0021.0025.0030.0033.0037.0040.0044.0046.0015.0013.0016.005.008.0010.007.008.00
    Cash Equivalents-2.6%9.0010.0014.0012.004.005.004.006.008.0012.0013.0041.0044.0013.0011.0014.003.006.007.005.006.00
  Inventory12.1%2.002.002.002.002.002.001.001.001.001.001.001.001.001.001.001.001.001.001.001.00-
  Net PPE11.9%1.001.001.001.001.001.001.001.001.001.001.000.000.000.000.000.000.001.001.001.000.00
Liabilities-14.8%7.008.007.007.006.007.006.007.005.006.006.006.005.006.004.005.004.004.004.004.004.00
  Current Liabilities-19.0%5.006.005.005.004.005.004.005.004.004.004.004.003.004.003.003.003.003.002.002.003.00
Shareholder's Equity-11.2%35.0040.0043.0047.0013.0017.0022.0026.0030.0034.0037.0041.0044.0012.0011.0013.003.005.008.006.006.00
  Retained Earnings-3.2%-228-221-216-210-205-201-196-192-187-183-179-174-171-168-164-162-159-157-155-153-150
  Additional Paid-In Capital1.0%264261259258219219219218217217216216215180176175163163163159156
Shares Outstanding7.2%23.0022.0021.0021.008.008.008.008.008.008.007.007.00---------
Float----46.00---16.00---39.00---16.00---5.00-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-21.2%-5,064-4,177-4,043-3,325-4,831-3,195-5,104-3,109-4,134-2,901-4,140-2,528-3,641-2,200-3,044-1,483-2,354-1,568-1,860-2,897-3,485
  Share Based Compensation58.8%2,6181,6491,62293028936865767465356630438332334514151.0069.0040.0010711068.00
Cashflow From Investing13480.6%4,817-36.006,386-26,8914,4493,8862,7541,866-65.001,841-24,184-90.00-24.00-104-49.00-31.00-3.00-69.00-94.00-119-105
Cashflow From Financing----37,534---103----35.001.0035,0684,06890.0012,2343.004.004,2852,03016.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

NSPR Income Statement

2024-03-31
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
REVENUES$ 1,511$ 1,239
COST OF REVENUES1,219866
GROSS PROFIT292373
OPERATING EXPENSES:  
Research and development2,6251,843
Selling and marketing1,237788
General and administrative3,8442,123
Total operating expenses7,7064,754
LOSS FROM OPERATIONS(7,414)(4,381)
FINANCIAL INCOME, net382125
NET LOSS$ (7,032)$ (4,256)
NET LOSS PER SHARE - basic$ (0.21)$ (0.53)
NET LOSS PER SHARE - diluted$ (0.21)$ (0.53)
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES USED IN COMPUTING NET LOSS PER SHARE - basic34,242,9768,093,340
WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES USED IN COMPUTING NET LOSS PER SHARE - diluted34,242,9768,093,340

NSPR Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
CURRENT ASSETS:  
Cash and cash equivalents$ 9,389$ 9,640
Marketable securities24,56129,383
Accounts receivable:  
Trade, net1,1871,804
Other483648
Prepaid expenses531578
Inventory2,3602,106
TOTAL CURRENT ASSETS38,51144,159
NON-CURRENT ASSETS:  
Property, plant and equipment, net1,1861,060
Operating lease right of use assets1,3661,473
Fund in respect of employee rights upon retirement965951
TOTAL NON-CURRENT ASSETS3,5173,484
TOTAL ASSETS42,02847,643
Accounts payable and accruals:  
Trade659939
Other4,2185,081
TOTAL CURRENT LIABILITIES4,8776,020
LONG-TERM LIABILITIES-  
Operating lease liabilities9141,038
Liability for employees rights upon retirement1,1501,084
TOTAL LONG-TERM LIABILITIES2,0642,122
COMMITMENTS AND CONTINGENT LIABILITIES
TOTAL LIABILITIES6,9418,142
EQUITY:  
Common stock, par value $0.0001 per share; 150,000,000 shares authorized at March 31, 2024 and December 31, 2023; 23,412,385 and 21,841,215 shares issued and outstanding at March 31, 2024 and December 2023, respectively22
Preferred C shares, par value $0.0001 per share; 1,172,000 shares authorized at March 31, 2024 and December 31, 2023; 1,718 shares issued and outstanding at March 31, 2024 and December 31 2023, respectively[1]
Additional paid-in capital263,618261,000
Accumulated deficit(228,533)(221,501)
Total equity35,08739,501
Total liabilities and equity$ 42,028$ 47,643
[1]Represents an amount less than $1 thousand
NSPR
InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Delivery System, a mesh-covered self-expanding carotid stent; SwitchGuard, a non-invasive transcarotid artery revascularization device; and NGuard EPS for treating acute stroke with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
 CEO
 WEBSITEinspiremd.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES55

InspireMD Inc Frequently Asked Questions


What is the ticker symbol for InspireMD Inc? What does NSPR stand for in stocks?

NSPR is the stock ticker symbol of InspireMD Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of InspireMD Inc (NSPR)?

As of Thu Jun 13 2024, market cap of InspireMD Inc is 64.82 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NSPR stock?

You can check NSPR's fair value in chart for subscribers.

What is the fair value of NSPR stock?

You can check NSPR's fair value in chart for subscribers. The fair value of InspireMD Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of InspireMD Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NSPR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is InspireMD Inc a good stock to buy?

The fair value guage provides a quick view whether NSPR is over valued or under valued. Whether InspireMD Inc is cheap or expensive depends on the assumptions which impact InspireMD Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NSPR.

What is InspireMD Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jun 13 2024, NSPR's PE ratio (Price to Earnings) is -2.86 and Price to Sales (PS) ratio is 10.01. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NSPR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on InspireMD Inc's stock?

In the past 10 years, InspireMD Inc has provided -0.826 (multiply by 100 for percentage) rate of return.